Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и терапия Ph-негаивных миелопролиферативных заболеваний

Литература

  • 1. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М., Зарицкий А.Ю., Афанасьев Б.В., Шуваев В.А. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014; 59(4): 31--56.
  • 2. Меликян А.Л., Туркина А.Г., Ковригина А.М., Суборцева И.Н., Судариков А.Б., Соколова М.А. и др. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017; 1(S1): 25-60.
  • 3. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937--951.
  • 4. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391--2405; doi: https://doi.org/10.1182/blood-2016-03-643544
  • 5. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных заболеваний. Клиническая онкогематология. 2016; 9 (3): 314--25. doi: 10.1182/blood-2009-03-209262.
  • 6. Pardanani A., Lasho T.L., Finke C., Hanson C.A., Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007; 21(9):1960--3. doi:10.1038/sj .leu.2404810
  • 7. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T. et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. Lancet. 2005; 366(9501): 1945--53. doi.org/10.1016/S0140-6736(05)67785-9
  • 8. Треглазова С.А., Абдуллаев А.О., Макарик Т.В., Суборцева И.Н., Меликян А.Л., Судариков А.Б. Исследование мутаций JAK2V617F, MPL W515L/K и 9 экзона гена CALR у пациентов с эссенциальной тромбоцитемией. Гематология и трансфузиология. 2016; 61(S1(1)): 74.
  • 9. Beer P.A., Campbell P.J., Scott LM, Bench A.J., Erber WN, Bareford D., et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008;112(1):141--149. doi: 10.1182/blood-2008-01-131664
  • 10. Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198--4200. doi: https://doi.org/10.1182/blood-2003-10-3471
  • 11. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et.al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391--405. doi: 10.1056/NEJMoa1312542
  • 12. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379--2390. doi: 10.1056/NEJMoa1311347
  • 13. Passamonti F., Rumi E., Pietra D., Elena C., Boveri E., Arcaini L. et al. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574--1579. doi: 10.1038/leu.2010.148.
  • 14. Varricchio L., Mancini A., Migliaccio A.R. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol. 2009; 2(3):315--334. doi: 10.1586/ehm.09.17
  • 15. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520--30.
  • 16. Cho S.Y., Xu M., Roboz J., Lu M., Mascarenhas J., Hoffman R. The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms. Cancer Res. 2010;70(8): 3402--10. doi: 10.1158/0008-5472.CAN-09-3977.
  • 17. Vannucchi A. M., T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. Kroger, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 (5): 85--99. doi: 10.1093/annonc/mdv203.
  • 18. Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. Москва: Литтерра; 2016: 2--298
  • 19. Thiele J., Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128--32.
  • 20. Воробьев А.И. Руководство по гематологии. Москва: Ньюдиамед; 2003: 9--15.
  • 21 Agarwal M. B., Malhotra H., Chakrabarti P., Varma N., Mathews V., Bhattacharyya J., et al. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol. 2015;36(1):3--16. doi: 10.4103/0971-5851.151770
  • 22. Busque L., Porwit A., Day R., Olney H.J., Leber B., Ethier V., et al. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group. Am J Clin Pathol. 2016;146(4):408--22. Doi: 10.1093/ajcp/aqw131.
  • 23. Mossuz P., Girodon F., Donnard M., Latger-Cannard V., Dobo I., Boiret N., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89(10): 1194--98.
  • 24. Subortseva I., Melikyan A., Kovrigina A., Kolosheynova T., Abdullaev A., Sudarikov A. et al. Clinical features of latent/masked polycythemia vera (single center experience). Haematologica. 2016;101(S1):812. https://www.researchgate.net/profile/Andrey_Sudarikov/publication/308693874_CLINICAL_FEATU RES_OF_LATENTMASKED_POLYCYTHEMIA_VERA_SINGLE_CENTER_EXPERIENCE/links /57eb6b0c08aeafc4e88a62fc.pdf?origin=publication_list
  • 25. Суборцева И.Н., Меликян А.Л., Ковригина А.М., Судариков А.Б. Латентная истинная полицитемия. Гематология и трансфузиология. 2016;61(1 приложение 1):72.
  • 26. Меликян А.Л., Суборцева И.Н. Материалы 56-го конгресса американского гематологического общества (декабрь 2014 г., Сан-Франциско) Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2015. 8(2). 201-232.
  • 27. Crisa E., Venturino E., Passera R., Prina M., Schinco P., Borchiellini A. et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691--99. doi: 10.1007/s00277-009-0899-z
  • 28. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И., Егорова Е.К., Ковригина А.М., Плискунова Ю.В. и др. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2015;8(4):397--412
  • 29. Michiels J.J., Berneman Z., Schroyens W., Finazzi G., Budde U., van Vliet H.H. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32(6):589--604
  • 30. Tefferi A., Rumi E., Finazzi G., Gisslinger H., Vannucchi A.M., Rodeghiero F., et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874--81. doi: 10.1038/leu.2013.163.
  • 31. Меликян А.Л., Суборцева И.Н. Материалы 19-го конгресса европейской гематологической ассоциации (2014 г., Милан). Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2014;7(4):598--607.
  • 32. Falchi L., Newberry K.J., Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):27--33. doi: 10.1016/j.clml.2015.02.013.
  • 33. Barosi G., Birgegard G., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H., et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961--3. doi: 10.1111/j.1365-2141.2009.08019.x.
  • 34. Bhatt D. L., Topol E. J. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev. 2003; 2(1): 15--28
  • 35. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008; 22(11): 1990--8. doi: 10.1038/leu.2008.280.
  • 36. Меликян А.Л., Суборцева И.Н. Миелопролиферативные новообразования: новые данные. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016;9 (2):218--228.
  • 37. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al.. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112(8): 3065--72. doi: 10.1182/blood-2008-03-143537.
  • 38. Quintas-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009; 27(32): 5418--24. doi: 10.1200/JCO.2009.23.6075.
  • 39. Them NC., Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am JHematol. 2015;90(4):288--94. doi: 10.1002/ajh.23928.
  • 40. И.Н. Суборцева, Е.А. Гилязитдинова, Т.И. Колошейнова, М.В. Калинина, Е.И. Пустовая, А.О. Абдуллаев и др. Предварительные результаты исследования по оценке эффективности и безопасности лечения пациентов с истинной полицитемией и эссенциальной тромбоцитемией цепэгинтерфероном альфа-2К Клиническая онкогематология. 2017; 10(4): 582 (Subortseva I.N., Giliazitdinova E.A., Kolosheinova T.I., Kalinina M.V., Pustovaia E.I., Abdullaev A.O., Sudarikov A.B., Melikian A.L. Preliminary results of a study to evaluate the efficacy and safety of treatment of patients with true polycythemia and essential thrombocythemia with cephagenephrine alpha-2b. Klinicheskaya onkogematologiya. 2017; 10(4): 582 [In Rus.]).
  • 41. А.Л. Меликян, И.Н. Суборцева, Е.А. Гилязитдинова, Т.И. Колошейнова, Е.И. Пустовая, Е.К. Егорова и др. Цепэгинтерферон альфа-Zb в лечении хронических миелопролиферативных заболеваний. Терапевтический архив. 2018. 9(7):23--29
  • 42. Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E. et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121(23): 4778--81. Doi: 10.1182/blood-2013-01-478891.
  • 43. Кузнецова П.И., Танашян М.М., Меликян А.Л., Лагода О.В., Суборцева И.Н. Цереброваскулярная патология при миелопролиферативных заболеваниях. Неврология и нейрохирургия. Восточная Европа. 2015;S: 44--46
  • 44. Танашян М.М., Кузнецова П.И., Лагода О.В., Шабалина А.А., Суборцева И.Н., Меликян А.Л. Миелопролиферативные заболевания и ишемический инсульт. Анналы клинической и экспериментальной неврологии. 2014;8 (2): 41--45.
  • 45. Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128--5133. doi: 10.1182/blood-2012-07-444067
  • 46. Alvarez-Larran A., Cervantes F., Pereira A., Arellano-Rodrigo E., Pёrez-Andreu V., Hernandez-Boluda J.C.et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205--10. doi: 10.1182/blood-2010-01-263319.
  • 47. Michiels J.J., Abels J., Steketee J., van Vliet H.H., Vuzevski V.D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med. 1985;102(4):466--71.
  • 48. Harrison C.N., Campbell P.J., Buck G., Wheatley K., East C.L., Bareford D., et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N. Engl. J. Med. 2005. 353(1): 33--45.
  • 49. Carobbio A., Finazzi G., Antonioli E., Vannucchi A.M., Barosi G., Ruggeri M,. et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by EuropeanLeukemiaNet criteria. Blood. 2010;116(7):1051--5. doi: 10.1182/blood-2010-03-272179.
  • 50. Storen E.C., Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001. 97(4): 863--866.
  • 51. Cervantes F., Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13): 2895--901.
  • 52. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Cazzola M. et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia inprimary myelofibrosis. Blood. 2010;116(15):2857--8. doi: 10.1182/blood-2010-06-293415.
  • 53. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S. et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. J. Clin. Oncol. 2011. 29(4). 392--7. doi: 10.1200/JCO.2010.32.2446.
  • 54. Tefferi A., Guglielmelli P., Finke C., Lasho T. L., Gangat N., Ketterling R., et al. Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis. Blood. 2014;124(21):406. doi: https://doi.org/
  • 55. de Melo Campos P. Primary myelofibrosis: current therapeutic options. Rev Bras Hematol Hemoter. 2016;38(3):257--63. doi: 10.1016/j.bjhh.2016.04.003.
  • 56. Kroger N.M., Deeg J.H., Olavarria E., Niederwieser D., Bacigalupo A., Barbui T., et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126--33. doi: 10.1038/leu.2015.233.
  • 57. Cervantes F., Alvarez-Larran A., Hernandez-Boluda J.-C. Sureda A., Torrebadell M., Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology. 2004. 127(4). 399--403.
  • 58. Quintas-Cardama A., Kantarjian H.M., Manshouri T., Thomas D., Cortes J., Ravandi F. et al. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. Journal of Clinical Oncology. 2009;27(28):4760--66. doi: 10.1200/JCO.2009.22.6548.
  • 59. Besa E.C., Nowell P.C., Geller N.L., Gardner F.H. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival. Cancer. 1982;49(2):308--313.
  • 60. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am JHematol. 2016;91(12):1262--1271. Doi: 10.1002/ajh.24592.
  • 61. Меликян А.Л., Колосова Л.Ю., Соколова М.А., Ковригина А.М., Силаев М.А., Гилязитдинова Е.А. и др. Роль спленэктомии при лечении больных миелофиброзом. Терапевтический архив. 2013; 85(8): 69--76.
  • 62. Melikyan A.L., Kovrigina А.М., Sokolova M.A., Kolosova L.U., Silaev M.A., Gilyazitdinova E.A., et al. The Role Of Splenectomy In The Treatment Of Myelofibrosis. Blood. 2013;122(21):4083 https://www.ncbi.nlm.nih.gov/pubmed/?term=Melikyan+A.L.%2C+Kovrigina+%D0%90.%D0%9C. %2C+Sokolova+M.A.%2C+Kolosova+L.U.%2C+Silaev+M.A.%2C+Gilyazitdinova+E.A.%2C+et+al .+The+Role+Of+Splenectomy+In+The+Treatment+Of+Myelofibrosis.+Blood.+2013%3B122(21)%3 A4083
  • 63. Doki N., Irisawa H, Takada S, Sakura T, Miyawaki S. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med. 2007;46(4):187--90.
  • 64. Harrison C.N. Kiladjan J., Al-Ali H.K., Gisslinger H., Waltzman R. J., Stalbovskaya V. et al. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or postessential thrombocythemia myelofibrosis (PET-MF). J. Clin. Oncol. 2011; 29(suppl): abstr LBA6501. http://www.researchtopractice.com/5MJCASCO2011/Myelofibrosis/2
  • 65. Mughal T.I., Vaddi K., Sarlis N.J., Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7(suppl):89--101. doi: 10.2147/IJGM.S51800.
  • 66. Neben-Wittich M.A., Brown P.D., Tefferi A.Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am. J. Hematol. 2010;85 (10):808--810.
  • 67. Mascarenhasa J., Heaneyb M.L., Najfelda V. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Res. 2012;36(12): 1500--04. doi: 10.1016/j.leukres.2012.08.013
  • 68. Tefferi A., Cervantes F., Mesa R., F. Passamonti, S. Verstovsek, A.M. Vannucchi et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122(8): 1395--1398. doi: 10.1182/blood-2013-03-488098
  • 69. Меликян А.Л., Суханова Г.А., Суборцева И.Н. Тромбогеморрагические осложнения и их лечение у больных эссенциальной тромбоцитемией. Вестник последипломного медицинского образования. 2013;3(suppl): 63.
  • 70. Шмаков Р.Г., Полушкина Е.С. Особенности репродуктивной функции у женщин с онкогематологическими заболеваниями. Современная онкология. 2008; 10(3):68--69

References российские источники должны быть оформлены аналогично примеру (_авторы - в транслитерации, после иниц, стоять точка, название статьи - в переводе на англ. язык, название журнала в переводе на англ. язык +_ в транслитерации, год, том, номер журнала, стр. от и до, далее в скобках (in Russian)

Автоматическую нумерацию источников удалите

  • 1. Melikyan A.L., Turkina A.G., Abdulkadyrov K.M., Zarickij A.YU., Afanas'ev B.V., SHuvaev V.A. et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis). Hematology and transfusiology. Gematologiya i transfuziologiya. 2014; 59(4): 31--56. (in Russian)
  • 2. Melikyan A.L., Turkina A.G., Kovrigina A.M., Subortceva I.N., Sudarikov A.B., Sokolova M.A. et al. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition of 2016). Hematology and transfusiology. Gematologiya i transfuziologiya. 2017; 1(S1): 25--60. (in Russian)
  • 3. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937--951.
  • 4. Arber D.A., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391--2405; doi: https://doi.org/10.1182/blood-2016-03-643544
  • 5. Melikyan A.L., Suborceva I.N. Biology of myeloproliferative diseases. Clinical oncohematology. Klinicheskaya onkogematologiya. 2016; 9 (3): 314--25. doi: 10.1182/blood-2009-03-209262. (in Russian)
  • 6. Pardanani A., Lasho T.L., Finke C., Hanson C.A., Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007; 21(9):1960--3. doi:10.1038/sj .leu.2404810
  • 7. Campbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., Marsden J.T. et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2V617F mutation status: a prospective study. Lancet. 2005; 366(9501): 1945--53. doi.org/10.1016/S0140-6736(05)67785-9
  • 8. Treglazova S.A., Abdullaev A.O., Makarik T.V., Suborceva I.N., Melikyan A.L., Sudarikov A.B. Study of mutations of JAK2V617F, MPL W515L / K and 9 exon of the CALR gene in patients with essential thrombocythemia. Hematology and transfusiology. Gematologiya i transfuziologiya. 2016; 61(S1(1)): 74. (in Russian)
  • 9. Beer P.A., Campbell P.J., Scott LM, Bench A.J., Erber WN, Bareford D., et al. MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort. Blood. 2008;112(1):141--149. doi: 10.1182/blood-2008-01-131664
  • 10. Ding J., Komatsu H., Wakita A., Kato-Uranishi M., Ito M., Satoh A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198--4200. doi: https://doi.org/10.1182/blood-2003-10-3471
  • 11. Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., et.al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391--405. doi: 10.1056/NEJMoa1312542
  • 12. Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013;369(25):2379--2390. doi: 10.1056/NEJMoa1311347
  • 13. Passamonti F., Rumi E., Pietra D., Elena C., Boveri E., Arcaini L. et al. A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574--1579. doi: 10.1038/leu.2010.148.
  • 14. Varricchio L., Mancini A., Migliaccio A.R. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol. 2009; 2(3):315--334. doi: 10.1586/ehm.09.17
  • 15. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520--30.
  • 16. Cho S.Y., Xu M., Roboz J., Lu M., Mascarenhas J., Hoffman R. The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative Neoplasms. Cancer Res. 2010;70(8): 3402--10. doi: 10.1158/0008-5472.CAN-09-3977.
  • 17. Vannucchi A. M., T. Barbui, F. Cervantes, C. Harrison, J.-J. Kiladjian, N. Kroger, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 (5): 85--99. doi: 10.1093/annonc/mdv203.
  • 18. Abdulkadyrov K.M., SHuvaev V.A., Martynkevich I.S. Myeloproliferative neoplasms. Moscow: Litterra, litterra; 2016: 2—298 (in Russian)
  • 19. Thiele J., Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128--32.
  • 20. Vorob'ev A.I. Guide to Hematology. Moscow: Newmediad; 2003: 9--15. (in Russian)
  • 21 Agarwal M. B., Malhotra H., Chakrabarti P., Varma N., Mathews V., Bhattacharyya J., et al. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol. 2015;36(1):3--16. doi: 10.4103/0971-5851.151770
  • 22. Busque L., Porwit A., Day R., Olney H.J., Leber B., Ethier V., et al. Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group. Am J Clin Pathol. 2016;146(4):408--22. Doi: 10.1093/ajcp/aqw131.
  • 23. Mossuz P., Girodon F., Donnard M., Latger-Cannard V., Dobo I., Boiret N., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89(10): 1194--98.
  • 24. Subortseva I., Melikyan A., Kovrigina A., Kolosheynova T., Abdullaev A., Sudarikov A. et al. Clinical features of latent/masked polycythemia vera (single center experience). Haematologica. 2016;101(S1):812. https://www.researchgate.net/profile/Andrey_Sudarikov/publication/308693874_CLINICAL_FEATU RES_OF_LATENTMASKED_POLYCYTHEMIA_VERA_SINGLE_CENTER_EXPERIENCE/links /57eb6b0c08aeafc4e88a62fc.pdf?origin=publication_list
  • 25. Suborceva I.N., Melikyan A.L., Kovrigina A.M., Sudarikov A.B. Latent polycythemia vera. Hematology and transfusiology. Gematologiya i transfuziologiya. 2016;61(1 приложение 1):72. (in Russian)
  • 26. Melikyan A.L., Suborceva I.N. Materials of the 56th Congress of the American Hematology Society (December 2014, San Francisco). Clinical oncohematology. Fundamental research and clinical practice. Klinicheskaya onkogematologiya fundamentalnye issledovaniya i klinicheskaya praktika. 2015. 8(2). 201-232. (in Russian)
  • 27. Crisa E., Venturino E., Passera R., Prina M., Schinco P., Borchiellini A. et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691--99. doi: 10.1007/s00277-009-0899-z
  • 28. Suborceva I.N., Koloshejnova T.I., Pustovaya E.I., Egorova E.K., Kovrigina A.M., Pliskunova YU.V. et.al. Polycythemia vera: a review of literature and our own data. Clinical oncohematology. Fundamental research and clinical practice. Klinicheskaya onkogematologiya fundamentalnye issledovaniya i klinicheskaya praktika. 2015;8(4):397--412 (in Russian)
  • 29. Michiels J.J., Berneman Z., Schroyens W., Finazzi G., Budde U., van Vliet H.H. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost. 2006;32(6):589--604
  • 30. Tefferi A., Rumi E., Finazzi G., Gisslinger H., Vannucchi A.M., Rodeghiero F., et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874--81. doi: 10.1038/leu.2013.163.
  • 31. Melikyan A.L., Suborceva I.N. Materials of the 19th Congress of the European Hematology Association (2014, Milan). Clinical oncohematology. Fundamental research and clinical practice. Klinicheskaya onkogematologiya fundamentalnye issledovaniya i klinicheskaya praktika. 2014;7(4):598--607. (in Russian)
  • 32. Falchi L., Newberry K.J., Verstovsek S. New Therapeutic Approaches in Polycythemia Vera. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):27--33. doi: 10.1016/j.clml.2015.02.013.
  • 33. Barosi G., Birgegard G., Finazzi G., Griesshammer M., Harrison C., Hasselbalch H., et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010;148(6):961--3. doi: 10.1111/j.1365-2141.2009.08019.x.
  • 34. Bhatt D. L., Topol E. J. Scientific and therapeutic advances in antiplatelet therapy. Nature Rev. 2003; 2(1): 15--28
  • 35. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008; 22(11): 1990--8. doi: 10.1038/leu.2008.280.
  • 36. Melikyan A.L., Suborceva I.N. Myeloproliferative neoplasms: new data. Clinical oncohematology. Fundamental research and clinical practice. Klinicheskaya onkogematologiya fundamentalnye issledovaniya i klinicheskaya praktika. 2016;9 (2):218--228. (in Russian)
  • 37. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al.. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112(8): 3065--72. doi: 10.1182/blood-2008-03-143537.
  • 38. Quintas-Cardama A., Kantarjian H., Manshouri T., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009; 27(32): 5418--24. doi: 10.1200/JCO.2009.23.6075.
  • 39. Them NC., Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, et al. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am JHematol. 2015;90(4):288--94. doi: 10.1002/ajh.23928.
  • 40. Subortseva I.N., Giliazitdinova E.A., Kolosheinova T.I., Kalinina M.V., Pustovaia E.I., Abdullaev A.O., Sudarikov A.B., Melikian A.L. Preliminary results of a study to evaluate the efficacy and safety of treatment of patients with true polycythemia and essential thrombocythemia with cephagenephrine alpha-2b. Clinical oncohematology. Klinicheskaya onkogematologiya. 2017; 10(4): 582 (in Russian)
  • 41. A.L. Melikyan, I.N. Suborceva, E.A. Gilyazitdinova, T.I. Koloshejnova, E.I. Pustovaya, E.K. Egorova et al. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases. Therapeutic archive. Terapevticheskij arhiv. 2018. 9(7):23--29
  • 42. Barosi G., Mesa R., Finazzi G., Harrison C., Kiladjian J.J., Lengfelder E. et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013; 121(23): 4778--81. Doi: 10.1182/blood-2013-01-478891.
  • 43. Kuznecova P.I., Tanashyan M.M., Melikyan A.L., Lagoda O.V., Suborceva I.N. Cerebrovascular pathology in myeloproliferative diseases. Neurology and Neurosurgery. Eastern Europe. Nevrologiya I nejrohirurgiya.Vostochnaya Evropa. 2015;S: 44—46 (in Russian)
  • 44. Tanashyan M.M., Kuznecova P.I., Lagoda O.V., SHabalina A.A., Suborceva I.N., Melikyan A.L. Myeloproliferative diseases and ischemic stroke. Annals of clinical and experimental neurology. Annaly klinicheskoj I ehksperimentalnoj nevrologii. 2014;8 (2): 41--45. (in Russian)
  • 45. Barbui T., Finazzi G., Carobbio A., Thiele J., Passamonti F., Rumi E. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128--5133. doi: 10.1182/blood-2012-07-444067
  • 46. Alvarez-Larran A., Cervantes F., Pereira A., Arellano-Rodrigo E., Pёrez-Andreu V., Hernandez-Boluda J.C.et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205--10. doi: 10.1182/blood-2010-01-263319.
  • 47. Michiels J.J., Abels J., Steketee J., van Vliet H.H., Vuzevski V.D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Int Med. 1985;102(4):466--71.
  • 48. Harrison C.N., Campbell P.J., Buck G., Wheatley K., East C.L., Bareford D., et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. N. Engl. J. Med. 2005. 353(1): 33--45.
  • 49. Carobbio A., Finazzi G., Antonioli E., Vannucchi A.M., Barosi G., Ruggeri M,. et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by EuropeanLeukemiaNet criteria. Blood. 2010;116(7):1051--5. doi: 10.1182/blood-2010-03-272179.
  • 50. Storen E.C., Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001. 97(4): 863--866.
  • 51. Cervantes F., Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13): 2895--901.
  • 52. Passamonti F., Cervantes F., Vannucchi A.M., Morra E., Rumi E., Cazzola M. et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia inprimary myelofibrosis. Blood. 2010;116(15):2857--8. doi: 10.1182/blood-2010-06-293415.
  • 53. Gangat N., Caramazza D., Vaidya R., George G., Begna K., Schwager S. et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. J. Clin. Oncol. 2011. 29(4). 392--7. doi: 10.1200/JCO.2010.32.2446.
  • 54. Tefferi A., Guglielmelli P., Finke C., Lasho T. L., Gangat N., Ketterling R., et al. Integration of mutations and karyotype towards a genetics-based prognostic scoring system (GPSS) for primary myelofibrosis. Blood. 2014;124(21):406. doi: https://doi.org/
  • 55. de Melo Campos P. Primary myelofibrosis: current therapeutic options. Rev Bras Hematol Hemoter. 2016;38(3):257--63. doi: 10.1016/j.bjhh.2016.04.003.
  • 56. Kroger N.M., Deeg J.H., Olavarria E., Niederwieser D., Bacigalupo A., Barbui T., et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015;29(11):2126--33. doi: 10.1038/leu.2015.233.
  • 57. Cervantes F., Alvarez-Larran A., Hernandez-Boluda J.-C. Sureda A., Torrebadell M., Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology. 2004. 127(4). 399--403.
  • 58. Quintas-Cardama A., Kantarjian H.M., Manshouri T., Thomas D., Cortes J., Ravandi F. et al. Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. Journal of Clinical Oncology. 2009;27(28):4760--66. doi: 10.1200/JCO.2009.22.6548.
  • 59. Besa E.C., Nowell P.C., Geller N.L., Gardner F.H. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival. Cancer. 1982;49(2):308--313.
  • 60. Tefferi A. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am JHematol. 2016;91(12):1262--1271. Doi: 10.1002/ajh.24592.
  • 61. Melikyan A.L., Kolosova L.YU., Sokolova M.A., Kovrigina A.M., Silaev M.A., Gilyazitdinova E.A. и др. The role of splenectomy in the treatment of patients with myelofibrosis. Therapeutic archive. Terapevticheskij arhiv. 2013; 85(8): 69--76. (in Russian)
  • 62. Melikyan A.L., Kovrigina А.М., Sokolova M.A., Kolosova L.U., Silaev M.A., Gilyazitdinova E.A., et al. The Role Of Splenectomy In The Treatment Of Myelofibrosis. Blood. 2013;122(21):4083 https://www.ncbi.nlm.nih.gov/pubmed/?term=Melikyan+A.L.%2C+Kovrigina+%D0%90.%D0%9C. %2C+Sokolova+M.A.%2C+Kolosova+L.U.%2C+Silaev+M.A.%2C+Gilyazitdinova+E.A.%2C+et+al .+The+Role+Of+Splenectomy+In+The+Treatment+Of+Myelofibrosis.+Blood.+2013%3B122(21)%3 A4083
  • 63. Doki N., Irisawa H, Takada S, Sakura T, Miyawaki S. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med. 2007;46(4):187--90.
  • 64. Harrison C.N. Kiladjan J., Al-Ali H.K., Gisslinger H., Waltzman R. J., Stalbovskaya V. et al. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or postessential thrombocythemia myelofibrosis (PET-MF). J. Clin. Oncol. 2011; 29(suppl): abstr LBA6501. http://www.researchtopractice.com/5MJCASCO2011/Myelofibrosis/2
  • 65. Mughal T.I., Vaddi K., Sarlis N.J., Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7(suppl):89--101. doi: 10.2147/IJGM.S51800.
  • 66. Neben-Wittich M.A., Brown P.D., Tefferi A.Successful treatment of severe extremity pain in myelofibrosis with low-dose single-fraction radiation therapy. Am. J. Hematol. 2010;85 (10):808--810.
  • 67. Mascarenhasa J., Heaneyb M.L., Najfelda V. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Res. 2012;36(12): 1500--04. doi: 10.1016/j.leukres.2012.08.013
  • 68. Tefferi A., Cervantes F., Mesa R., F. Passamonti, S. Verstovsek, A.M. Vannucchi et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013; 122(8): 1395--1398. doi: 10.1182/blood-2013-03-488098
  • 69. Melikyan A.L., Suhanova G.A., Suborceva I.N. Thrombohemorrhagic complications and their treatment in patients with essential thrombocythemia. Bulletin of Postgraduate Medical Education. Vestnik poslediplomnogo medicinskogo obrazovaniya. 2013;3(suppl): 63. (in Russian)
  • 70. Шмаков Р.Г., Полушкина Е.С. Особенности репродуктивной функции у женщин с онкогематологическими заболеваниями. Современная онкология. 2008; 10(3):68--69

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Оглавление

Данный блок поддерживает скрол*